Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/de/projects/887-a-multicenter-non-randomized-open-label-phase-1b-study-to-determine-the-maximum-tolerated-and-recommended-phase-2-dose-of-the-atr-inhibitor-bay-1895344-in-combination-with-pembrolizumab-and-characterize-its-safety-tolerability-pharmacokinetics-and-preliminiary-anti-tumor-activity-in-patients-with-advanced-solid-tumors/publications